- Conditions
- Open-angle Glaucoma, Ocular Hypertension
- Interventions
- High Dose Drug Device, Low Dose Drug Device, Placebo Device, bimatoprost 0.03%
- Drug
- Lead sponsor
- Vistakon Pharmaceuticals
- Industry
- Eligibility
- 21 Years and older
- Enrollment
- 47 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2009
- U.S. locations
- 5
- States / cities
- Miami, Florida • Philadelphia, Pennsylvania • Mt. Pleasant, South Carolina + 2 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 56
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Insulin Resistance, Prediabetic State, Non-Alcoholic Fatty Liver Disease, Overweight and Obesity
- Interventions
- Insulin human, Octreotide Acetate, Glucagon, Human Growth Hormone, Dexamethasone Oral, [6,6-2H2] D-glucose, 20% D-glucose (aq), BOOST Plus, Harvard Apparatus PHD ULTRA CP syringe pump, Yellow Springs Instruments (YSI) 2500 Biochemistry Glucose/Lactate Analyzer, Normal saline, Human albumin
- Drug · Other · Dietary Supplement + 1 more
- Lead sponsor
- Columbia University
- Other
- Eligibility
- 18 Years to 65 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2026
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Cigarette Smoking, Drug Use
- Interventions
- Standard Treatment, BAD-AS, Transdermal Nicotine Patch
- Behavioral · Drug
- Lead sponsor
- University of Maryland, College Park
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 96 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2015
- U.S. locations
- 1
- States / cities
- Washington D.C., District of Columbia
- Conditions
- Stage D Heart Failure
- Interventions
- Sacubitril-Valsartan, Usual care (standard-of-care) arm
- Drug
- Lead sponsor
- The Cleveland Clinic
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2022
- U.S. locations
- 1
- States / cities
- Cleveland, Ohio
- Conditions
- Glioblastoma, Recurrent Glioblastoma, GBM
- Interventions
- SonoCloud-9 (SC9), Carboplatin, Lomustine, Temozolomide
- Device · Drug
- Lead sponsor
- CarThera
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 560 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2028
- U.S. locations
- 23
- States / cities
- Phoenix, Arizona • Los Angeles, California • San Francisco, California + 16 more
- Conditions
- Quality of Life, Fatigue
- Interventions
- UVL1000 Treatment Station, Normal Saline Solution, Peripheral Catheterization
- Device · Drug
- Lead sponsor
- UVLrx Therapeutics
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 3,063 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2014 – 2016
- U.S. locations
- 1
- States / cities
- Dallas, Texas
- Conditions
- Hematologic Malignancies
- Interventions
- CliniMACS® CD34 Reagent System, Fludarabine, Melphalan, anti-thymocyte globulin (rabbit), Rituximab, Total Body Irradiation, Mycophenolate Mofetil, Tacrolimus
- Device · Drug · Radiation
- Lead sponsor
- Weill Medical College of Cornell University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 270 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2026
- U.S. locations
- 2
- States / cities
- Chicago, Illinois • New York, New York
- Conditions
- Pain
- Interventions
- UVL1000 Treatment Station, Normal Saline 0.9% Infusion Solution Bag, Peripheral Catheterization
- Device · Drug
- Lead sponsor
- John W. Reeves, MD
- Other
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 150 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2017 – 2018
- U.S. locations
- 1
- States / cities
- Shreveport, Louisiana
- Conditions
- Respiratory Insufficiency, Extracorporeal Membrane Oxygenation Complication, Mechanical Ventilation Pressure High
- Interventions
- Ultra-Protective Ventilation Facilitated by Extracorporeal Support, Lung-Protective Ventilation (LPV), Driving Pressure-Limited Ventilation (DPL), Lung- and Diaphragm-Protective Ventilation and Sedation (LDPVS), Early Cohort corticosteroid dose, Extended Cohort corticosteroid dose, Usual care without routine corticosteroids, Usual care without extending corticosteroids, Usual care with fludrocortisone, Usual care without fludrocortisone, Drug 4 mL:, Drug 40 mg:, PEEP-20, PEEP-AOP, PEEP-10, VV ECMO-facilitated strategy of earlier awakening, extubation and rehabilitation, Electrical impedance tomography (EIT), no treatment / intervention arm is involved., Usual care, Early Routine IMT
- Other · Drug
- Lead sponsor
- University Health Network, Toronto
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 6,250 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2027
- U.S. locations
- 26
- States / cities
- Tucson, Arizona • Los Angeles, California • San Diego, California + 19 more
- Conditions
- Diabetes Mellitus, Type 1
- Interventions
- Insulin Lispro, ZP4207 (dasiglucagon), Glucagon, iPhone-based bionic pancreas, iLet-based bionic pancreas
- Drug · Device
- Lead sponsor
- Zealand Pharma
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 13 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2017
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Osteoporosis
- Interventions
- abaloparatide-sMTS (Patheon), abaloparatide-sMTS (Kindeva)
- Combination Product
- Lead sponsor
- Radius Health, Inc.
- Industry
- Eligibility
- 40 Years to 65 Years · Female only
- Enrollment
- 36 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2020 – 2021
- U.S. locations
- 1
- States / cities
- Cincinnati, Ohio
- Conditions
- Non-syndromic Retinitis Pigmentosa
- Interventions
- Gene therapy: GS030-DP AND Medical device: GS030-MD
- Combination Product
- Lead sponsor
- GenSight Biologics
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2027
- U.S. locations
- 1
- States / cities
- Pittsburgh, Pennsylvania
- Conditions
- Chronic Low-back Pain
- Interventions
- PainGuide, MBSR, PT and exercise, Self -administered acupressure, Duloxetine, Pro-Diary monitor
- Behavioral · Device · Drug
- Lead sponsor
- University of Michigan
- Other
- Eligibility
- 25 Years to 70 Years
- Enrollment
- 494 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2025
- U.S. locations
- 1
- States / cities
- Ann Arbor, Michigan
- Conditions
- Coronavirus, Covid19
- Interventions
- bamlanivimab 7000mg, BRII-196+BRII-198, AZD7442 (IV), AZD7442 (IM), SNG001, Camostat, BMS-986414 + BMS-986413, SAB-185 (3,840 Units/kg), SAB-185 (10,240 Units/kg), CASIRIVIMAB + IMDEVIMAB, Placebo for Bamlanivimab 7000mg, Placebo for Bamlanivimab 700mg, Placebo for BRII-196+BRII-198, Placebo for SNG001, Placebo for Camostat, Placebo for SAB-185 (low dose), Placebo for BMS-986414 + BMS-986413, Placebo for AZD7442 (IV), Placebo for AZD7442 (IM), Placebo for SAB-185 (high dose), bamlanivimab 700mg
- Biological · Drug
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 4,044 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2023
- U.S. locations
- 207
- States / cities
- Anniston, Alabama • Athens, Alabama • Birmingham, Alabama + 143 more
- Conditions
- Smoking Cessation
- Interventions
- Questionnaires, Low Dose Computed Tomography Scan, Shared Decision Making + Video, Cessation Counseling, Quitline, Pharmacotherapy Discussion, Nicotine Patch, Anti-Smoking Drug, Tobacco Treatment Program, Carbon Monoxide (CO) Level Test
- Behavioral · Procedure · Other + 1 more
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 50 Years and older
- Enrollment
- 630 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2017 – 2026
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Asthma
- Interventions
- FS MDPI, Fp MDPI, Placebo MDPI, albuterol/salbutamol, Beclomethasone dipropionate
- Drug
- Lead sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 787 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2015
- U.S. locations
- 76
- States / cities
- Birmingham, Alabama • Glendale, Arizona • Cypress, California + 64 more
- Conditions
- Glaucoma, Open-Angle, Ocular Hypertension
- Interventions
- PA5108 Ocular Implant low dose, PA5108 Ocular Implant, high dose, Latanoprost 0.005% Ophthalmic Solution
- Combination Product · Drug
- Lead sponsor
- PolyActiva Pty Ltd
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 75 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2026
- U.S. locations
- 1
- States / cities
- Newport Beach, California
- Conditions
- Tobacco Use Disorder
- Interventions
- Nicotine Patch, Sustained Release Bupropion
- Drug
- Lead sponsor
- University of Tennessee
- Other
- Eligibility
- 18 Years to 45 Years
- Enrollment
- 594 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2004 – 2008
- U.S. locations
- 1
- States / cities
- Memphis, Tennessee
- Conditions
- Glaucoma, Open-Angle, Ocular Hypertension
- Interventions
- High Dose Device, Low Dose Device, Placebo Device
- Drug · Device
- Lead sponsor
- Vistakon Pharmaceuticals
- Industry
- Eligibility
- 21 Years and older
- Enrollment
- 55 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2009
- U.S. locations
- 4
- States / cities
- Artesia, California • Louisville, Kentucky • Baltimore, Maryland + 1 more
- Conditions
- Rhinitis, Sinusitis
- Interventions
- Quinine Sulfate, Placebo
- Drug
- Lead sponsor
- University of Pennsylvania
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2017
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Asthma
- Interventions
- Daily Text message reminder, Inhaled steroid canister monitor
- Behavioral · Device
- Lead sponsor
- Children's Hospital of Philadelphia
- Other
- Eligibility
- 4 Years to 11 Years
- Enrollment
- 41 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2016
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Bronchiolitis Obliterans, Chronic Rejection of Lung Transplant, Lung Transplant Rejection, Lung Transplant; Complications, Lung Transplant Failure and Rejection, Chronic Lung Allograft Dysfunction
- Interventions
- Liposomal Cyclosporine A, Standard of Care
- Drug
- Lead sponsor
- Zambon SpA
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 169 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2024
- U.S. locations
- 21
- States / cities
- Phoenix, Arizona • Los Angeles, California • Palo Alto, California + 16 more
- Conditions
- Hearing Loss, Depression
- Interventions
- Phonak Audeo B-R 90 hearing aid device (Active), Duloxetine or escitalopram, Audeo B-R 90 hearing aid device (Sham)
- Device · Drug
- Lead sponsor
- New York State Psychiatric Institute
- Other
- Eligibility
- 60 Years to 99 Years
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2021
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- COVID-19
- Interventions
- REGN10933+REGN10987 combination therapy, Placebo
- Drug
- Lead sponsor
- Regeneron Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 2,252 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2021
- U.S. locations
- 96
- States / cities
- Birmingham, Alabama • Chandler, Arizona • Phoenix, Arizona + 70 more